sales@jinjingroup.com

  News Introduction

Innovative drugs such as 3,4-dihydroxybenzaldehyde(cas 139-85-5) is imperative

Date : 2016/8/26 13:44:57

In recent years, the government attaches great importance to technological innovation and the pharmaceutical industry, invested tens of millions each year to develop new drugs, but this is far from the scale of a medium-sized companies compared with foreign drug development level. After the implementation of pharmaceutical patent protection, generic drugs became less and less, and take the road of independent development of innovative drugs such as 3,4-dihydroxybenzaldehyde(cas 139-85-5) is imperative.

To achieve this goal, research and development has become a key drug intermediates. Research and development of new varieties of modern medicine and new proprietary formulation; the relationship of people's lives and health and to improve the quality of life and focuses on hot areas, especially in major changes to adapt to the modern disease spectrum disease control drugs, Advancing Genetic Engineering drugs and chemicals to create new drugs.

Pharmaceutical intermediate(3,4-dihydroxybenzaldehyde(cas 139-85-5)) product planning and development direction:

Engineering Technology Research Center should be able to quickly and reliably deliver the required market production technology for the production sector, while development of the industry play a leading role. According to Jiangsu Province, "three-drug" project development plan, the development direction of the focus on drug intermediates heterocyclic compounds, fluorine-containing synthetic compounds, chiral compounds, biological compounds.

Pharmaceutical intermediates industry  is a branch of the chemical industry, after nearly 30 years of development, has become the new industry output value of billions of dollars, it also will become more intense competition. In the early development of the industry, because a smaller investment, high return, pharmaceutical intermediates enterprise mushroomed rise.